SCHEMBL7238664

SCHEMBL7238664

COc1cncc(C(=O)CN)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
MAP4K4 O95819 1/20 0.42
CYP11B1 P15538 3/20 0.41
CYP11B2 P19099 3/20 0.41
TDP1 Q9NUW8 2/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CLK2 P49760 1/20 0.39
CLK3 P49761 1/20 0.39
DYRK1A Q13627 1/20 0.39
PARP1 P09874 1/20 0.39
ATM Q13315 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7240593 0.98 MKNK1 (0.48) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL10475039 0.85 MKNK1 (0.44) MKNK1MKNK2CYP11B1CYP11B2TDP1
SCHEMBL30734351 0.84 MKNK1 (0.46) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL8240390 0.84 MKNK1 (0.46) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL17518860 0.83 GSK3B (0.56) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL17819556 0.81 MKNK1 (0.44) MKNK1MKNK2CYP11B1CYP11B2TDP1
Bromide SCHEMBL17503995 0.81 GSK3B (0.54) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL9448469 0.80 MKNK1 (0.66) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL1863209 0.80 MKNK1 (0.43) MKNK1MKNK2MAP4K4CYP11B1CYP11B2
SCHEMBL18246429 0.79 KDM4E (0.57) MKNK1MKNK2TDP1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242426-B1 GAMMA-HYDROXY-2-(FLUOROALKYLAMINOCARBONYL)-1-PIPERAZINEPENTANAMIDES AS HIV PROTEASE INHIBITORS MERCK & CO INC (US) 2007-10-31 EP disclosed
US-6649761-B2 Viricides such as 4-(1-(5-(5-methoxy-3-pyridinyl)-carbonyl-methylaminocarbonyl)-1-methylethyl)-2(S)-((2,2,2-trifluoro-ethyl)aminocarbonyl)-1-(allyloxycarbonyl)piperazine and salts formed by decarboxylation using acids, then purifying MERCK & CO., INC. 2003-11-18 US disclosed
US-20030144512-A1 Process for preparing piperazinepentaneamide HIV protease inhibitors MERCK & CO., INC. 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144512-A1 Process for preparing piperazinepentaneamide HIV protease inhibitors NPEPPS, PREP, DNPEP MKNK1 1686/4885MKNK2 1661/4885MAP4K4 1250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.